Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line Bruton tyrosine kinase inhibitors among elderly patients ≥65 years in chronic lymphocytic leukemia
Authors:
Open Access
- 14 February 2026
- journal article
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 19 (5) , 539-546
Abstract
Chronic lymphocytic leukemia (CLL) commonly affects older patients, who often endure greater health disparities and treatment burdens. This study assessed treatment utilization patterns, discontinuation, and healthcare resource utilization (HCRU) of first-line (1 L) use of Bruton tyrosine kinase inhibitors (BTKis) in elderly patients with CLL. A retrospective observational study using Symphony Integrated Dataverse identified CLL patients aged ≥65 years initiating a 1 L BTKi (zanubrutinib, acalabrutinib, ibrutinib; 01/2022-11/2024). Baseline characteristics and outcomes were reported for each BTKi. Treatment discontinuation rate was estimated at 3, 4, 5, 6, 12, 18, and 24 months, and by time to discontinuation (TTD), using Kaplan-Meier method. HCRU (outpatient, inpatient, and other services) was evaluated as per-patient-per-year (PPPY). A total of 5344 patients ≥65 years were included (acalabrutinib = 2,662; zanubrutinib = 1,577; ibrutinib = 1,105). Baseline characteristics were similar across each BTKi. Zanubrutinib had the longest median TTD overall (zanubrutinib: 22.8 months, acalabrutinib: 17.4 months, ibrutinib: 14.3 months; p < .0001). Average outpatient visits PPPY were lowest for zanubrutinib (zanubrutinib: 9.7, acalabrutinib: 10.9, ibrutinib: 11.5; p = .0018). This real-world study demonstrated that zanubrutinib was associated with longer TTD, lower discontinuation rates, and less HCRU compared to acalabrutinib or ibrutinib in older CLL patients aged ≥65 years.Keywords
Funding Information
- BeOne Medicines, Ltd
This publication has 31 references indexed in Scilit:
- Too frail or not too frail? Prognosis and treatment options in older CLL patientsmemo - Magazine of European Medical Oncology, 2025
- Real-world characteristics, treatment patterns, and outcomes of patients with 2 or more LOTs for CLL/SLL in the United StatesBlood Neoplasia, 2024
- Safety profile of first-line targeted therapies in elderly and/or comorbid chronic lymphocytic leukaemia patients (unfit subpopulation). A systematic review and network meta-analysisCritical Reviews in Oncology/Hematology, 2024
- Prognosis of older adults with chronic lymphocytic leukemia: A Surveillance, Epidemiology, and End Results-Medicare cohort studyJournal of Geriatric Oncology, 2023
- EE407 Healthcare Resource Utilization and Cost Burden of Facial Angiofibroma Associated with Tuberous Sclerosis Complex: A Real-World Claims Database Analysis in the United StatesValue in Health, 2023
- Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International StudyClinical Lymphoma Myeloma and Leukemia, 2023
- Diagnosis and Treatment of Chronic Lymphocytic LeukemiaJAMA, 2023
- Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2021
- PCN124 REAL-WORLD HEALTHCARE RESOURCE UTILIZATION AND TOTAL COST OF CARE AMONG US MEDICARE PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA RECEIVING FIRST-LINE IBRUTINIB VS CHEMOIMMUNOTHERAPYValue in Health, 2020
- CLL Therapy: Focus on Comorbidities, Not AgeCaring for the Ages, 2015